Medifocus Inc. Extends Closing Date of Private Placement

(NOT FOR DISSEMINATION IN THE UNITED STATES OF AMERICA)

Medifocus Inc. (Medifocus) (TSX VENTURE:MFS)(OTCQX:MDFZF) announces that,
subject to regulatory approval, it has extended to on or around September 21,
2012 the closing date for its previously announced non-brokered private
placement. The Offering was originally announced on July 6, 2012 and is for up
to 26,666,666 units (the Units) at a price of $0.15 per Unit for anticipated
gross proceeds of up to $4,000,000 (the Offering). 


All other terms and conditions of the Offering remain unchanged.

About Medifocus 

Medifocus owns a patented microwave focusing technology platform (the Adaptive
Phased Array ("APA") technology), which can precisely target and control
microwave energy to cause heating in cancerous tumors anywhere in the body
reliably and repeatedly. The ability to target tumors with a precision
controlled dose of heat can be used to destroy tumors at higher temperatures, to
treat tumors in combination with chemotherapy and/or radiation at moderate
temperatures for increased effectiveness and reduced toxicity and to trigger the
targeted release of therapeutic drugs and genes at tumor sites at lower
temperatures. While the core technology has been licensed from the Massachusetts
Institute of Technology, Medifocus has further refined the precision of the
microwave focusing and control ability and developed a commercial system
dedicated exclusively for the treatment of Breast Cancer. With the acquisition
of Prolieve, Medifocus now owns in addition, a revenue generating commercial BPH
heat treatment product generating cash flow to support the development and
commercialization of other catheter based or APA based external focused heat
systems for targeted thermotherapy of deep seated tumors anywhere in the body.
Please visit www.medifocusinc.com for more details.